journal article·2018-04

Therapeutic effects of gefitinib-encapsulated thermosensitive injectable hydrogel in intervertebral disc degeneration

Zongyou Pan, Heng Sun, Binbin Xie, Dongdong Xia, Xiaoan Zhang, Dongsheng Yu, Jun Li, Yuzi Xu, Zuhua Wang, Yan Wu, Xiaolei Zhang, Yafei Wang, Qianbao Fu, Wei Hu, Yang Yang, Varitsara Bunpetch, Weiliang Shen, Boon Chin Heng, Shufang Zhang, Hongwei Ouyang

Biomaterials· Volume 160
Publisher page

Abstract

Intervertebral disc (IVD) degeneration is one of the most widespread musculoskeletal diseases worldwide, which remains an intractable clinical challenge. The aim of this study is to investigate the therapeutic potential of the small molecule gefitinib (an epidermal growth factor receptor (EGFR) inhibitor) in ameliorating IVD degeneration. Aberrant EGFR activation levels were detected in both human and rat degenerative IVDs, which prompted us to investigate the functional roles of EGFR by utilizing inducible cartilage-specific EGFR-deficient mice. We demonstrated that conditional EGFR deletion in mice increased nucleus pulposus (NP) extracellular matrix (ECM) production and autophagy marker activation while MMP13 expression decreased. These outcomes are comparable to the use of a controlled-release injectable thermosensitive hydrogel of gefitinib to block EGFR activity in a puncture-induced rat model. We also conducted a case series study involving patients with non-small cell lung cancer and IVD degeneration who received gefitinib treatment from 2010 to 2015. Gefitinib-treated patients displayed a relative slower disc degenerating progression, in contrast to control subjects. These findings thus provide evidence that suppression of EGFR by the FDA-approved drug gefitinib can protect IVD degeneration in rats, implying the potential application of gefitinib as a small molecule drug for treating IVD degeneration.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Spine and Intervertebral Disc Pathology · Spinal Hematomas and Complications · Cancer Treatment and Pharmacology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (44)

Show source-provided references
1. Stem cell therapy for intervertebral disc regeneration: obstacles and solutions10.1038/nrrheum.2015.13 ↗
2. Role of cytokines in intervertebral disc degeneration: pain and disc content10.1038/nrrheum.2013.160 ↗
3. Intervertebral disc regeneration: do nutrients lead the way?10.1038/nrrheum.2014.91 ↗
4. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 (vol 380, pg 2163, 2012)
5. Diversity of intervertebral disc cells: phenotype and function
6. Anatomy and Biomechanics of the Spinal Column and Cord
7. New in vivo measurements of pressures in the intervertebral disc in daily life10.1097/00007632-199904150-00005 ↗
8. Human mesenchymal stem cell differentiation to NP-like cells in chitosan-glycerophosphate hydrogels10.1016/j.biomaterials.2007.09.018 ↗
9. Current understanding of cellular and molecular events in intervertebral disc degeneration: implications for therapy10.1002/path.1050 ↗
10. 'Stress' distributions inside intervertebral discs. The effects of age and degeneration10.1302/0301-620X.78B6.0780965 ↗
11. Internal intervertebral-disk mechanics as revealed by stress profilometry10.1097/00007632-199201000-00011 ↗
12. Biomechanical comparison between fusion of two vertebrae and implantation of an artificial intervertebral disc10.1016/j.jbiomech.2004.07.039 ↗
13. Complications in lumbar fusion surgery for chronic low back pain: comparison of three surgical techniques used in a prospective randomized study. A report from the Swedish Lumbar Spine Study Group10.1007/s00586-002-0493-8 ↗
14. Adjacent segment degeneration and adjacent segment disease: the consequences of spinal fusion?10.1016/j.spinee.2004.07.007 ↗
15. Recurrent disc herniation and long-term back pain after primary lumbar discectomy: review of outcomes reported for limited versus aggressive disc removal10.1227/01.NEU.0000337574.58662.E2 ↗
16. Homing of mesenchymal stem cells in induced degenerative intervertebral discs in a whole organ culture system10.1097/BRS.0b013e3182544a8a ↗
17. EGF-ERBB signalling: towards the systems level10.1038/nrm1962 ↗
18. Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease10.1073/pnas.0505171102 ↗
19. Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo10.1186/ar4233 ↗
20. Transforming growth factor alpha suppression of articular chondrocyte phenotype and Sox9 expression in a rat model of osteoarthritis10.1002/art.22968 ↗
21. The critical role of the epidermal growth factor receptor in endochondral ossification10.1002/jbmr.502 ↗
22. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma10.1016/j.jhep.2004.08.024 ↗
23. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis10.1002/hep.20538 ↗
24. Hydrogels in acellular and cellular strategies for intervertebral disc regeneration10.1002/term.500 ↗
25. A simple disc degeneration model induced by percutaneous needle puncture in the rat tail10.1097/BRS.0b013e31817c64a9 ↗
26. Magnetic resonance classification of lumbar intervertebral disc degeneration10.1097/00007632-200109010-00011 ↗
27. Col2CreER(T2), a mouse model for a chondrocyte-specific and inducible gene deletion10.22203/eCM.v028a16 ↗
28. 1997 Volvo Award winner in basic science studies - immunohistologic markers for age-related changes of human lumbar intervertebral discs10.1097/00007632-199712150-00001 ↗
29. Thermosensitive injectable hyaluronic acid hydrogel for adipose tissue engineering10.1016/j.biomaterials.2009.08.058 ↗
30. Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin10.1016/j.actbio.2012.09.034 ↗
31. An in vivo model of degenerative disc disease10.1016/S0736-0266(02)00098-0 ↗
32. Relationship of Modic type 1 change with disc degeneration: a prospective MRI study10.1007/s00256-008-0611-8 ↗
33. Specific growth factors during the expansion and redifferentiation of adult human articular chondrocytes enhance chondrogenesis and cartilaginous tissue formation in vitro10.1002/1097-4644(20010501)81:2<368::AID-JCB1051>3.0.CO;2-J ↗
34. Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes10.1074/jbc.M211360200 ↗
35. Activation of epidermal growth factor receptor gene is involved in transforming growth factor-beta-mediated fibronectin expression in a chondrocyte progenitor cell line
36. Global analyses of gene expression in early experimental osteoarthritis10.1002/art.22711 ↗
37. Rho/ROCK and MEK/ERK activation by transforming growth factor-alpha induces articular cartilage degradation10.1038/labinvest.2009.111 ↗
38. An in vivo model of degenerative disc disease10.1016/S0736-0266(02)00098-0 ↗
39. Autophagy in the pathogenesis of disease10.1016/j.cell.2007.12.018 ↗
40. EGFR-Mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and Tumor Chemoresistance10.1016/j.cell.2013.08.015 ↗
41. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy10.1002/jcb.24465 ↗
42. Autophagy is activated in compression-induced cell degeneration and is mediated by reactive oxygen species in nucleus pulposus cells exposed to compression10.1016/j.joca.2013.10.002 ↗
43. Autophagy attenuates the catabolic effect during inflammatory conditions in nucleus pulposus cells, as sustained by NF-kappa B and JNK inhibition10.3892/ijmm.2015.2280 ↗
44. Analgesic effect of gefitinib in the treatment of non-small cell lung cancer